NRX Pharmaceuticals’ 2025 Q4 Earnings Call: Shifting Commercialization Strategy and NDA Timeline Clash With Prior Statements

Date of Call: Mar 24, 2026

Guidance:

• KETAFREE (preservative-free ketamine) ANDA approval anticipated for summer 2026.
• Potential for FDA approval of NRX-100 (ketamine) by year-end 2026 or in early 2027.
• Aim to reach pro forma profitability by year-end 2026.
• Ongoing operations supported by cash resources through 2026.

Business Commentary:

Progress in Drug Approvals:

• NRx Pharmaceuticals advanced its drug development with a drug approval anticipated for KETAFREE over the summer, potential for a drug approval this year for NRX-100, and a dramatically expanded opportunity for NRX-101.
• The company achieved a preliminary determination of bioequivalence for KETAFREE, and the FDA policy change allowed the use of real-world evidence to strengthen the case for NRX-100 approval.

Financial Improvements:

• NRx reduced its loss from operations by approximately $2.3 million to $16.2 million from $18.5 million for the year ended December 31, 2024, primarily due to decreased research and development expenses.
• The company eliminated all convertible debt and ended the year with $7.8 million in cash, sufficient to support operations through 2026.

HOPE Therapeutics Growth:

• HOPE Therapeutics clinics demonstrated EBITDA positive revenue growth, with the first acquisition in September 2025 and additional sites added, contributing to the company's revenue generation.
• The expansion of the clinic network aims to provide integrated care and leverage partnerships with medical device manufacturers to enhance treatment outcomes.

Clinical and Market Expansion:

• The company experienced transformative change in the NRX-101 program, identifying a broader potential application for D-cycloserine in augmenting transcranial magnetic stimulation (TMS) efficacy.
• NRx launched a nationwide expanded access program and plans to start a confirmatory phase III trial, supported by non-dilutive federal sources, with an estimated market exceeding $1 billion.

FDA Engagement and Strategic Positioning:

• FDA's willingness to review real-world evidence and guidance to seek full approval for NRX-100, along with an expanded Fast Track designation, positioned NRx to pursue a broader indication for depression.
• The strategic partnership with neurocare group AG aims to integrate pharmaceutical and medical device development, mirroring successful models in other healthcare sectors.

Sentiment Analysis:

Overall Tone: Positive

• Management describes 2025 as 'a pivotal and transformative year,' with 'dramatically expanded opportunity' for NRX-101 and progress towards three potential near-term drug approvals. They state the company is 'a far stronger company than when the year began,' has 'generated revenue, we expect to increase revenue,' and that 'our goal of bringing hope to life is closer than ever.'

Q&A:

• Question from Thomas Shrader (BTIG): Update on building KETAFREE inventory and confidence in pricing if it were the only preservative-free ketamine.
  Response: Management has already manufactured 3 registration batches and will produce 200,000 units in anticipation of approval; believes market demand would likely support a price increase if it were the only preservative-free option.

• Question from Thomas Shrader (BTIG): On extended release D-cycloserine (NRX-101), is there clinical data needed to prove the sustained release has the same effects?
  Response: Believes the neuroplastic effect can be validated in vitro; steady-state drug exposure is likely more effective for biological response, and clinical work is planned.

• Question from Patrick R. Trucchio (H.C. Wainwright & Co.): Details on the FDA Type C meeting and how real-world data enables an NDA filing for NRX-100 without additional trials.
  Response: FDA did not demand additional clinical trials as a precondition; they will review existing clinical trial data and real-world evidence from ~65,000 patients, which demonstrates the efficacy and safety of intravenous ketamine.

• Question from Patrick R. Trucchio (H.C. Wainwright & Co.): Impact of a broader treatment-resistant depression label for NRX-100 on payer coverage and prescriber adoption.
  Response: A broader label targeting ~12 million patients with depression and potential suicidal ideation is more attractive to payers, who have indicated willingness to cover treatments under $10,000 per year, similar to the market dynamics for Spravato.

• Question from Patrick R. Trucchio (H.C. Wainwright & Co.): What remains before KETAFREE ANDA approval after the preliminary bioequivalence determination.
  Response: The Office of Generic Drugs will complete its review, including stability data examination and a pre-approval plant inspection, but clearing bioequivalence is a major turning point.

• Question from Edward Moon (Ascendiant Capital Markets): Commercial strategy for KETAFREE if approved in Q3 2026.
  Response: Plans to leverage existing distribution channels for hospitals and a targeted medical liaison service for clinics, expecting a compact and financiable commercial footprint.

Contradiction Point 1

Commercialization Strategy for NRX-100 (Preservative-Free Ketamine)

Strategy shifts from a small medical liaison force to leveraging distributors for hospitals.

Edward Moon (Ascendiant Capital Markets) - Edward Moon (Ascendiant Capital Markets)

2025Q4: For hospitals, the company plans to leverage existing distributors rather than build its own sales force. - Dr. Jonathan Javitt(CEO)

Can you discuss the commercialization strategy following Q3 2026 ANDA approval? - Edward Woo (Ascendiant Capital Markets LLC)

2025Q3: NRX-100...can be launched with a medical science liaison function rather than a large sales force. - Dr. Jonathan Javitt(CEO)

Contradiction Point 2

Status of the NDA Filing for NRX-100

Timeline changes from pending CNPV outcome to being enabled by a Type C meeting.

Patrick R. Trucchio (H.C. Wainwright & Co.) - Patrick R. Trucchio (H.C. Wainwright & Co.)

2025Q4: The FDA did not require additional clinical trials as a precondition for the NDA filing, allowing the submission... - Dr. Jonathan Javitt(CEO)

How does the Type C meeting with the FDA enable an NDA filing for NRX-100 without additional clinical trials? - Patrick Trucchio (H.C. Wainwright & Co, LLC)

2025Q3: The NDA for NRX-100 has not been fully filed yet pending CNPV outcome. - Jonathan Javitt(CEO)

Contradiction Point 3

Commercialization Strategy for NRX-100

Contradiction on the scale and structure of the commercial team needed for launch.

Edward Moon (Ascendiant Capital Markets) - Edward Moon (Ascendiant Capital Markets)

2025Q4: For clinics, a small medical liaison service will be established to cover known clinic networks efficiently, representing a compact and financiable commercial footprint. - Dr. Jonathan Javitt(CEO)

Discuss your commercialization strategy assuming ANDA approval in Q3 2026? - Edward Moon Woo (Ascendiant Capital Markets)

2025Q2: For **NRX-100**, targeting ~600-1,000 mental health clinics could be managed with a **commercial team of ~20 people** (reps + MSLs). - Matthew Patrick Duffy(Chief Business Officer)

Contradiction Point 4

Vision for Hope Therapeutics

Contradiction on whether Hope Therapeutics will become an independent company.

Edward Moon (Ascendiant Capital Markets) - Edward Moon (Ascendiant Capital Markets)

2025Q4: The company plans to leverage existing distributors rather than build its own sales force. - Dr. Jonathan Javitt(CEO)

What is your commercialization strategy assuming ANDA approval in Q3 2026? - Jason Howard Kolbert (D. Boral Capital)

2025Q2: The vision is for **Hope Therapeutics to become an independent company** with a national presence... - Jonathan C. Javitt(CEO)

Contradiction Point 5

KETAFREE Inventory Timeline and Availability

Contradiction on the readiness and timing of KETAFREE product inventory prior to approval.

Thomas Shrader (BTIG) - Thomas Shrader (BTIG)

2025Q4: Three registration batches of KETAFREE are already manufactured and in the warehouse. A first production run of 200,000 units is anticipated to be ready in the warehouse at the time of generic approval... - Dr. Jonathan Javitt(CEO)

What is your current strategy for building KETAFREE inventory? - Edward Woo (Ascendiant Capital)

2025Q1: The company intends to make NRX-100 available more broadly internationally... The company has been approached by several international entities for this purpose. - Jonathan Javitt(CEO)